JAK2 V617F Mutant-Selective Allosteric Inhibitors therapy (Atavistik Bio)

N/A

Report date: 2025/12/05 14:12:27

NME

Base Information

Drug NameJAK2 V617F Mutant-Selective Allosteric Inhibitors therapy (Atavistik Bio)

Drug Alias NameN/A

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionJAK2 V617F inhibitors

TargetsJAK2 V617F

Therapy Area/IndicationsMyeloproliferative Disorders

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAtavistik Bio Inc

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsMyeloproliferative Disorders

Inactive IndicationsN/A

ATC CodeN/A